JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO
B5846 Radotinib(IY-5511)

Target: PDGFR|Bcr-Abl

Summary: Bcr-Abl tyrosine kinase inhibitor

≥13.73 mg/mL
B7354 SU 16f

Target: PDGFR

Summary: PDGFRβ inhibitor

Soluble in DMSO
A8476 MK-2461

Target: FLT3|PDGFR|MET|Ron

Summary: C-Met (WT/mutants) inhibitor

≥24.8 mg/mL
A8394 CHIR-124

Target: FLT3|GSK-3|Chk|PDGFR

Summary: Chk1 inhibitor,novel and potent

insoluble in H2O; ≥10.5 mg/mL
B2172 PP121

Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck

Summary: Dual inhibitor of tyrosine and phosphoinositide kinases
B2173 CP-673451

Target: PDGFR

Summary: PDGFRα/β inhibitor,potent and selective
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL